Dr. Reddy’s Labs’ Q4 FY24 displays a 36% YoY net profit rise, hitting ₹1,307 Cr.
Revenue soars to ₹7,083 Cr, a 12% YoY rise, and EPS jumps to ₹78.53. EBITDA stands strong at ₹1,872 Cr.
Gross Margin reaches 58.6%. Dividend of ₹40/share recommended.
The Company's focus on R&D yields results. 3 new brands launched in India. Gross Margin up by 140 bps.
Dr. Reddy’s Lab's commitment to cost-effective healthcare propels growth.